Not independent
Tenure on this board
4.6 yrs
Meeting calendar
IMMX · Annual meeting · Friday, May 22, 2026
Immix Biopharma Inc
9 nominees · 2 ballot items.
Vote to elect nine directors to the Board and to ratify Crowe LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year.
Market cap
$558M
1Y TSR
+272.9%
Board grade
B+
Record date
Mar 31, 2026
Filing
DEF 14A
Meeting concluded · May 22, 2026
Follow how the vote landed and what changed on Immix Biopharma Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect nine director nominees named in the proxy statement to serve until the next annual meeting and until their successors are duly elected and qualified.
- 2
Ratification of the Appointment of Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026
ManagementBoard: FORRatify the Audit Committee’s appointment of Crowe LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot9
Not independent
Tenure on this board
4.6 yrs
Independent
Tenure on this board
4.6 yrs
Independent
Tenure on this board
4.6 yrs
Also a director at
Arcturus Therapeutics Holdings Inc (ARCT)Transcode Therapeutics Inc (RNAZ)First Tracks Biotherapeutics Inc (TRAX)
Independent
Tenure on this board
4.6 yrs
Independent
Tenure on this board
4.6 yrs
Independent
Tenure on this board
4.6 yrs
Independent
Tenure on this board
2.9 yrs
Also a director at
Elicio Therapeutics Inc (ELTX)
Not independent
Tenure on this board
0.9 yrs
Also a director at
W&T Offshore Inc (WTI)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 8.8% | 4,802,002 | $44M |
| 2 | Saturn V Capital Management LP | 6.8% | 3,693,585 | $34M |
| 3 | EVENTIDE ASSET MANAGEMENT, LLC | 4.7% | 2,549,019 | $23M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 1,787,994 | $16M |
| 5 | MILLENNIUM MANAGEMENT LLC | 3.2% | 1,750,200 | $16M |
| 6 | Logos Global Management LP | 2.3% | 1,225,000 | $11M |
| 7 | Bleichroeder LP | 1.8% | 1,000,000 | $9M |
| 8 | FRANKLIN RESOURCES INC | 1.8% | 969,066 | $9M |
| 9 | MARSHALL WACE, LLP | 1.5% | 817,710 | $7M |
| 10 | Velan Capital Investment Management LP | 1.4% | 740,000 | $7M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Immix Biopharma Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$712M
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Reference
Frequently asked questions
- When is the Immix Biopharma Inc 2026 annual meeting?
- Immix Biopharma Inc (IMMX) holds its 2026 annual shareholder meeting on Friday, May 22, 2026.
- What is the record date for the Immix Biopharma Inc 2026 meeting?
- The record date for the Immix Biopharma Inc 2026 meeting is Tuesday, March 31, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Immix Biopharma Inc's 2026 meeting?
- The board is presenting 9 director nominees at the Immix Biopharma Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Immix Biopharma Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Immix Biopharma Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.